Aurinia completes enrollment of AURORA, its phase 3 clinical trial for treatment of LN
Aurinia Pharmaceuticals announced it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis patients randomized in sites across 27 countries. September 25, 2018